

2019 Future of Post-Traumatic Stress Disorder (PTSD) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2DB4613F305EN.html>

Date: February 2019

Pages: 110

Price: US\$ 2,199.00 (Single User License)

ID: 2DB4613F305EN

Abstracts

The global demand for Post-Traumatic Stress Disorder (PTSD) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Post-Traumatic Stress Disorder (PTSD) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Post-Traumatic Stress Disorder (PTSD) pipeline companies from advancing their products into Phase 3 or Phase 4.

Post-Traumatic Stress Disorder (PTSD) Report Description-

The 2019 pipeline study on Post-Traumatic Stress Disorder (PTSD) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Post-Traumatic Stress Disorder (PTSD) pipeline compounds.

The Post-Traumatic Stress Disorder (PTSD) pipeline guide presents information on all active drugs currently being developed for Post-Traumatic Stress Disorder (PTSD). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-

registration phases.

Details of current status, R&D progress and latest developments for every Post-Traumatic Stress Disorder (PTSD) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Post-Traumatic Stress Disorder (PTSD) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Post-Traumatic Stress Disorder (PTSD) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Post-Traumatic Stress Disorder (PTSD) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Post-Traumatic Stress Disorder (PTSD) pipeline report includes-

An overview of Post-Traumatic Stress Disorder (PTSD) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Post-Traumatic Stress Disorder (PTSD) pipeline

Company wise list of Post-Traumatic Stress Disorder (PTSD) pipeline

Mechanism of Action wise Post-Traumatic Stress Disorder (PTSD) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Post-Traumatic Stress Disorder (PTSD) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Post-Traumatic Stress Disorder (PTSD) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Post-Traumatic Stress Disorder (PTSD) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Post-Traumatic Stress Disorder (PTSD) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Post-Traumatic Stress Disorder (PTSD) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Post-Traumatic Stress Disorder (PTSD) Pipeline Candidates

4 ACTINOGEN MEDICAL LTD POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 4.1 Actinogen Medical Ltd Business Profile
- 4.2 Actinogen Medical Ltd Post-Traumatic Stress Disorder (PTSD) Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography

- 4.3.6 Type of Molecular Entity
- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ADDEX THERAPEUTICS LTD POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 5.1 Addex Therapeutics Ltd Business Profile
- 5.2 Addex Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AMORSA THERAPEUTICS INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 6.1 Amorsa Therapeutics Inc Business Profile
- 6.2 Amorsa Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview

- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 ANAGIN INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 7.1 Anagin Inc Business Profile
- 7.2 Anagin Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 APTINYX INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 8.1 Aptinyx Inc Business Profile
- 8.2 Aptinyx Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 ARMGO PHARMA INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 9.1 Armgo Pharma Inc Business Profile
- 9.2 Armgo Pharma Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 9.3 Drug Snapshot
 - 9.3.1 Originator
 - 9.3.2 Collaborator/Co-Developer
 - 9.3.3 Route of Administration
 - 9.3.4 Orphan Drug/Fast Track/Special Designation
 - 9.3.5 Geography
 - 9.3.6 Type of Molecular Entity
 - 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 AZEVAN PHARMACEUTICALS INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 10.1 Azevan Pharmaceuticals Inc Business Profile
- 10.2 Azevan Pharmaceuticals Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 BIONOMICS LTD POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 11.1 Bionomics Ltd Business Profile
- 11.2 Bionomics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography
 - 11.3.6 Type of Molecular Entity
 - 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 CATALYST PHARMACEUTICALS INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 12.1 Catalyst Pharmaceuticals Inc Business Profile
- 12.2 Catalyst Pharmaceuticals Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 CHRONOS THERAPEUTICS LTD POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 13.1 Chronos Therapeutics Ltd Business Profile
- 13.2 Chronos Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Details
- 13.3 Drug Snapshot

- 13.3.1 Originator
- 13.3.2 Collaborator/Co-Developer
- 13.3.3 Route of Administration
- 13.3.4 Orphan Drug/Fast Track/Special Designation
- 13.3.5 Geography
- 13.3.6 Type of Molecular Entity
- 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 CORCEPT THERAPEUTICS INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 14.1 Corcept Therapeutics Inc Business Profile
- 14.2 Corcept Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 ELI LILLY AND CO POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 15.1 Eli Lilly and Co Business Profile
- 15.2 Eli Lilly and Co Post-Traumatic Stress Disorder (PTSD) Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration

- 15.3.4 Orphan Drug/Fast Track/Special Designation
- 15.3.5 Geography
- 15.3.6 Type of Molecular Entity
- 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 EMBERA NEUROTHERAPEUTICS INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 16.1 Embera NeuroTherapeutics Inc Business Profile
- 16.2 Embera NeuroTherapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 EPIVARIO INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 17.1 EpiVario Inc Business Profile
- 17.2 EpiVario Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography

- 17.3.6 Type of Molecular Entity
- 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 HMNC BRAIN HEALTH POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 18.1 HMNC Brain Health Business Profile
- 18.2 HMNC Brain Health Post-Traumatic Stress Disorder (PTSD) Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration
 - 18.3.4 Orphan Drug/Fast Track/Special Designation
 - 18.3.5 Geography
 - 18.3.6 Type of Molecular Entity
 - 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 IGC PHARMA POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 19.1 IGC Pharma Business Profile
- 19.2 IGC Pharma Post-Traumatic Stress Disorder (PTSD) Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview

- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 IMMODULON THERAPEUTICS LTD POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 20.1 Immodulon Therapeutics Ltd Business Profile
- 20.2 Immodulon Therapeutics Ltd Post-Traumatic Stress Disorder (PTSD) Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 JOHNSON & JOHNSON POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 21.1 Johnson & Johnson Business Profile
- 21.2 Johnson & Johnson Post-Traumatic Stress Disorder (PTSD) Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 KDAC THERAPEUTICS INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 22.1 Kdac Therapeutics Inc Business Profile
- 22.2 Kdac Therapeutics Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 NEURONASCENT INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 23.1 NeuroNascent Inc Business Profile
- 23.2 NeuroNascent Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 NEURORX INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 24.1 NeuroRx Inc Business Profile
- 24.2 NeuroRx Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25 NEUROVATION LABS INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 25.1 Neurovation Labs Inc Business Profile
- 25.2 Neurovation Labs Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 25.3 Drug Snapshot
 - 25.3.1 Originator
 - 25.3.2 Collaborator/Co-Developer
 - 25.3.3 Route of Administration
 - 25.3.4 Orphan Drug/Fast Track/Special Designation
 - 25.3.5 Geography
 - 25.3.6 Type of Molecular Entity
 - 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26 OMEROS CORPORATION POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 26.1 Omeros Corporation Business Profile
- 26.2 Omeros Corporation Post-Traumatic Stress Disorder (PTSD) Drug Details

- 26.3 Drug Snapshot
 - 26.3.1 Originator
 - 26.3.2 Collaborator/Co-Developer
 - 26.3.3 Route of Administration
 - 26.3.4 Orphan Drug/Fast Track/Special Designation
 - 26.3.5 Geography
 - 26.3.6 Type of Molecular Entity
 - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27 ONE WORLD CANNABIS LTD POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 27.1 One World Cannabis Ltd Business Profile
- 27.2 One World Cannabis Ltd Post-Traumatic Stress Disorder (PTSD) Drug Details
- 27.3 Drug Snapshot
 - 27.3.1 Originator
 - 27.3.2 Collaborator/Co-Developer
 - 27.3.3 Route of Administration
 - 27.3.4 Orphan Drug/Fast Track/Special Designation
 - 27.3.5 Geography
 - 27.3.6 Type of Molecular Entity
 - 27.3.7 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28 OTSUKA HOLDINGS CO LTD POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 28.1 Otsuka Holdings Co Ltd Business Profile
- 28.2 Otsuka Holdings Co Ltd Post-Traumatic Stress Disorder (PTSD) Drug Details
- 28.3 Drug Snapshot
 - 28.3.1 Originator
 - 28.3.2 Collaborator/Co-Developer

- 28.3.3 Route of Administration
- 28.3.4 Orphan Drug/Fast Track/Special Designation
- 28.3.5 Geography
- 28.3.6 Type of Molecular Entity
- 28.3.7 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29 PRAGMA THERAPEUTICS SAS POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 29.1 Pragma Therapeutics SAS Business Profile
- 29.2 Pragma Therapeutics SAS Post-Traumatic Stress Disorder (PTSD) Drug Details
- 29.3 Drug Snapshot
 - 29.3.1 Originator
 - 29.3.2 Collaborator/Co-Developer
 - 29.3.3 Route of Administration
 - 29.3.4 Orphan Drug/Fast Track/Special Designation
 - 29.3.5 Geography
 - 29.3.6 Type of Molecular Entity
 - 29.3.7 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details
- 29.7 Latest Drug Developments

30 QUOIN PHARMACEUTICALS LTD POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 30.1 Quoin Pharmaceuticals Ltd Business Profile
- 30.2 Quoin Pharmaceuticals Ltd Post-Traumatic Stress Disorder (PTSD) Drug Details
- 30.3 Drug Snapshot
 - 30.3.1 Originator
 - 30.3.2 Collaborator/Co-Developer
 - 30.3.3 Route of Administration
 - 30.3.4 Orphan Drug/Fast Track/Special Designation
 - 30.3.5 Geography

- 30.3.6 Type of Molecular Entity
- 30.3.7 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31 SPRINGWORKS THERAPEUTICS LLC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 31.1 SpringWorks Therapeutics LLC Business Profile
- 31.2 SpringWorks Therapeutics LLC Post-Traumatic Stress Disorder (PTSD) Drug Details
- 31.3 Drug Snapshot
 - 31.3.1 Originator
 - 31.3.2 Collaborator/Co-Developer
 - 31.3.3 Route of Administration
 - 31.3.4 Orphan Drug/Fast Track/Special Designation
 - 31.3.5 Geography
 - 31.3.6 Type of Molecular Entity
 - 31.3.7 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

32 TONIX PHARMACEUTICALS HOLDING CORP POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 32.1 Tonix Pharmaceuticals Holding Corp Business Profile
- 32.2 Tonix Pharmaceuticals Holding Corp Post-Traumatic Stress Disorder (PTSD) Drug Details
- 32.3 Drug Snapshot
 - 32.3.1 Originator
 - 32.3.2 Collaborator/Co-Developer
 - 32.3.3 Route of Administration
 - 32.3.4 Orphan Drug/Fast Track/Special Designation
 - 32.3.5 Geography
 - 32.3.6 Type of Molecular Entity

- 32.3.7 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

33 TRIMARAN PHARMA INC POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE DETAILS

- 33.1 TRImaran Pharma Inc Business Profile
- 33.2 TRImaran Pharma Inc Post-Traumatic Stress Disorder (PTSD) Drug Details
- 33.3 Drug Snapshot
 - 33.3.1 Originator
 - 33.3.2 Collaborator/Co-Developer
 - 33.3.3 Route of Administration
 - 33.3.4 Orphan Drug/Fast Track/Special Designation
 - 33.3.5 Geography
 - 33.3.6 Type of Molecular Entity
 - 33.3.7 Current Status
- 33.4 Drug Overview
- 33.5 Drug Mechanism of Action
- 33.6 Clinical/Pre-clinical Trial Details
- 33.7 Latest Drug Developments

34. LATEST POST-TRAUMATIC STRESS DISORDER (PTSD) DRUG PIPELINE DEVELOPMENTS, 2019

35. APPENDIX

- 35.1 About Us
- 35.2 Sources and Methodology
- 35.3 Contact Information

I would like to order

Product name: 2019 Future of Post-Traumatic Stress Disorder (PTSD) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2DB4613F305EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2DB4613F305EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970